IP Library Granted Patent US 10,842,740
Granted Patent B2
US 10,842,740 · App. 16/826,485 · Granted Nov 24, 2020

Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia

Inventor: Praful Doshi (San Diego, CA)
A61K9/0051A61K31/5377A61L27/54A61L31/06A61L31/10A61L31/145A61L31/16B33Y80/00C08F2/20C08F2/48C08F220/28C08L33/08C08L33/10G02B1/043A61L12/00A61L12/084A61L12/143A61L2300/00A61L2300/436A61L2420/08C08L33/066C08L39/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,842,740
App. No.
16/826,485
Granted
Nov 24, 2020
Kind
B2
Abstract

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat, prevent from having, prevent from developing, control, reduce the severity, or reduce the progression of a disease, disorder or condition of a subject.

Claims (62)

1. A method of making a medical device contact lens for delivery of drug to the eye of a subject in need of treatment, prevention, reduction of severity, or reduction of progression of myopia, or a combination thereof, comprising:

1) providing a contact lens comprising a first surface and a second surface; and

2) depositing at least one coating on at least one of said first surface, said second surface, or a combination thereof;

i. wherein said depositing comprises at least in part additive digital three dimensional printing;

ii. further wherein said at least one coating comprises at least one three dimensional structure, said at least one three dimensional structure comprising:

i) at least one drug reservoir layer,

wherein said at least one drug reservoir layer comprises at least one drug to treat, prevent, reduce the severity of, reduce the progression of myopia, or a combination thereof; and

ii) at least one barrier layer;

wherein said at least one barrier layer can modulate the release of said at least one drug from said medical device.

2. The method of making a medical device contact lens of claim 1 ,

wherein said medical device is stored in a packaging solution.

3. The method of making a medical device contact lens of claim 2 ,

wherein said packaging solution comprises at least one comfort enhancing agent.

4. The method of making a medical device contact lens of claim 2 ,

wherein said packaging solution comprises one or more drugs.

5. The method of making a medical device contact lens of claim 4 ,

wherein said one or more drugs comprises an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

6. The method of making a medical device contact lens of claim 4 ,

wherein said one or more drugs comprises atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

7. The method of making a medical device contact lens of claim 1 ,

wherein said at least one drug comprises an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

8. The method of making a medical device contact lens 1 ,

wherein said at least one drug comprises atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

9. The method of making a medical device of claim 1 , wherein said contact lens comprises a soft contact lens, a hydrogel contact lens, a silicone hydrogel contact lens, a hard contact lens, a gas permeable contact lens, or a combination thereof.

10. The method of making a medical device of claim 1 wherein said contact lens comprises a pre-made contact lens or a pre-manufactured contact lens.

11. The method of making a medical device of claim 1 , wherein said at least one coating is made in whole or in part by digital printing, 3D printing, digital 3D printing, or a combination thereof.

12. A method of using a medical device contact lens for delivery of at least one drug to the eye of a subject in need of treatment, prevention, control, reduction of the severity, or reduction of progression of myopia, comprising:

a) providing a subject in need of treatment, prevention, control, or reduction of the severity of myopia;

b) operably engaging a medical device contact lens comprising one or more drugs with at least one eye of said subject;

wherein said medical device contact lens comprises:

a) a contact lens comprising a first surface and a second surface;

b) said contact lens further comprising at least one coating provided on at least a portion of said first surface, said second surface, or a combination thereof as opposed to within said contact lens, wherein said at least one coating comprises at least one drug;

1) said at least one coating comprising at least one three dimensional structure;

2) said at least one three dimensional structure comprising:

a. one or more drug reservoir layers; wherein said one or more drug reservoir layers comprise at least one drug; and

b. one or more barrier layers;

c) wherein said one or more barrier layers modulate the release of said one or more drugs from said contact lens;

d) wherein said one or more drug reservoir layers, said one or more barrier layers, or a combination thereof, are oriented vertically, horizontally, or a combination thereof, relative to each other;

further wherein said at least one drug can treat, prevent, control, reduce the severity, or reduce the progression of myopia in a subject in need thereof; and

further wherein said at least one drug is released from said contact lens in a pharmaceutically effective amount to treat, prevent, control, reduce the severity, or reduce the progression of myopia in a subject when said medical device is operably engaged with the eye of said subject.

13. The method of using a medical device contact lens of claim 12 ,

wherein said medical device contact lens is stored in a packaging solution.

14. The method of using a medical device contact lens of claim 13 ,

wherein said packaging solution comprises one or more comfort enhancing agents.

15. The medical device of claim 14 ,

further wherein said one or more comfort enhancing agents is provided within said contact lens, on the surface of said contact lens, or a combination thereof.

16. The method of using a medical device contact lens of claim 13 ,

wherein said packaging solution comprises one or more drugs.

17. The method of using a medical device contact lens of claim 16 ,

wherein said one or more drugs comprise an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

18. The method of using a medical device contact lens of claim 16 ,

wherein said one or more drugs comprise atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

19. The method of using a medical device contact lens of claim 12 ,

wherein said at least one drug comprise an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

20. The method of using a medical device contact lens of claim 12 ,

wherein said at least one drug comprise atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

21. The method of using a medical device contact lens of claim 12 ,

wherein said medical device is provided as part of a system to treat, prevent, control, reduce the severity, or reduce the progression of myopia in a subject.

22. The method of using a medical device contact lens of claim 21 ,

wherein said system comprises at least one packaging, at least one set of instructions, at least one solution, or a combination thereof.

23. The method of using a medical device contact lens of claim 12 ,

wherein said contact lens comprises a multi-focal contact lens, a bifocal contact lens, orthokeratology contact lens, corrective contact lens, non-corrective contact lens, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2023
From: DOSHI, PRAFUL
To: MEDIPRINT OPHTHALMICS INC.
Reel/Frame 062806/0864 →
Continuity (11)
Continuation 16524015 · Jul 27, 2019
Division 16188833 · Nov 13, 2018
Continuation In Part 16158587 · Oct 12, 2018
Continuation 16023156 · Jun 29, 2018
Division 15898329 · Feb 16, 2018
Division 15891456 · Feb 8, 2018
Division 13065904 · Apr 2, 2011
Provisional Application 61341824 · Apr 3, 2010
Provisional Application 62677021 · May 27, 2018
Provisional Application 62597272 · Dec 11, 2017
Related Publication 20200268649A1 · Aug 27, 2020